Top
Raghu Kalluri, M.D., Ph.D.

BY Jill Russell, Ph.D.

A study published in JAMA comparing adverse event outcomes by treatment type for patients with localized prostate cancer reveals most...

BY Clayton Boldt

Prostate cancer is the most common cancer diagnosed in American men, and the second leading cause of cancer death in men. While hormone-based...

BY Ron Gilmore

Just as a driver’s night vision improves by simply cleaning the headlights, scientists at The University of Texas MD Anderson Cancer Center have discovered that removing an unwanted element from a protein known to suppress the immune system may eventually help clinicians better observe which cancer patients will benefit by treatment with immune checkpoint blockades.

Heng-Huan Lee, Ph.D., a postdoctoral fellow and Ying-Nai Wang,...

Glycans attach to the PD-L1 protein on tumors, making it hard to detect. MD Anderson researchers have found that purging glycans makes PD-L1 easier to find and accurately assess. Image courtesy of Cancer Cell.

BY Clayton R. Boldt, Ph.D.

MD Anderson’s proteomics platform provides a valuable institutional resource, complete with state-of-the-art instruments and specialized expertise...

BY MD Anderson staff

This is the second part of Cancer Frontline’s interview with Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology...

BY MD Anderson staff

In October 2018, the Nobel Prize in Physiology or Medicine was awarded to Jim Allison, Ph.D., chair of Immunology, for his discoveries on...

BY Clayton R. Boldt, Ph.D.

Excluding skin cancers, prostate cancer is the most commonly diagnosed cancer among men in the United States. According to the American Cancer...

BY Ron Gilmore

Reported online in the July 28 issue of Molecular Cell, a study conducted at MD Anderson has shown that a protein called ZMYND8 blocks expression...

BY Ron Gilmore

New findings about where and how aggressive forms of prostate cancer potentially begin may lead to new therapies for hard-to-treat and lethal...